Back to discover

Protein / target

Short transient receptor potential channel 6

Encoded byTRPC6Q9Y210Homo sapiensSwiss-Prot
Small-molecule tractable
Druggability
Structure with Ligand
2
Research papers

Protein at a glance

Biological role

Store-operated calcium channel

Strongest disease association

Nephrotic Syndrome

Via encoding gene TRPC6 · Genetic evidence · score 0.75

Research activity

Emerging research

2 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Non-selective, calcium-permeable cation channel.

View complete UniProt function annotation

Non-selective, calcium-permeable cation channel (PubMed:19936226, PubMed:23291369, PubMed:26892346, PubMed:9930701). Mediates calcium entry following G(q)-coupled receptor or receptor tyrosine kinase activation, which triggers phospholipase C (PLC)-mediated hydrolysis of phosphatidylinositides and production of diacylglycerol (DAG) that directly activates TRPC6 (PubMed:26892346). Does not appear to be activated by depletion of intracellular calcium stores (PubMed:9930701). Mediates depolarization of intrinsically photosensitive retinal ganglion cells (ipRGCs) in response to light-induced melanopsin (OPN4)-mediated phototransduction via G(q)-PLC signaling, likely by forming heteromeric TRPC6-TRPC7 channels (By similarity)

Subcellular location

Cell membrane
Domains and Gene Ontology detail (16)

Gene Ontology

  • Ccation channel complex
  • Ccytoplasm
  • Cmembrane
  • Cplasma membrane
  • Cslit diaphragm
  • Fcalcium channel activity
  • Finositol 1,4,5 trisphosphate binding
  • Fmonoatomic cation channel activity
  • Fprotein homodimerization activity
  • Fstore-operated calcium channel activity
  • Pcalcium ion transmembrane transport
  • Pmonoatomic cation transport

931 aa · 106 kDa · 3 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Ion channel gatingGOReceptor tyrosine kinase signallingUniProt
View supporting evidence

Ion channel gating

  • ·monoatomic cation channel activity
  • ·calcium ion transmembrane transport
  • ·positive regulation of ion transmembrane transporter activity

Receptor tyrosine kinase signalling

  • ·Non-selective, calcium-permeable cation channel (PubMed:19936226, PubMed:23291369, PubMe…

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene TRPC6

Gene-level evidence surfaced through the gene TRPC6that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Nephrotic Syndrome
0.76Well supported

Genetic evidence dominant · Open Targets 0.46

Smoking initiation
0.56Moderately supported

Genetic evidence dominant · Open Targets 0.34

Genetic Diseases, Inborn
0.56Moderately supported

Genetic evidence dominant · Open Targets 0.34

Immune System Diseases
0.51Moderately supported

Genetic evidence dominant · Open Targets 0.31

Poisoning
0.51Moderately supported

Genetic evidence dominant · Open Targets 0.31

View evidence synthesis (5)
Nephrotic SyndromeWell supported
0.76
agreement 0.620.90
Genetic97%Literature3%

Open Targets aggregate 0.46 · 2 independent evidence families

Smoking initiationModerately supported
0.56
agreement 0.450.69
Genetic100%

Open Targets aggregate 0.34 · 1 independent evidence family

Genetic Diseases, InbornModerately supported
0.56
agreement 0.420.70
Genetic99%Literature1%

Open Targets aggregate 0.34 · 2 independent evidence families

Immune System DiseasesModerately supported
0.51
agreement 0.370.65
Genetic100%Literature0%

Open Targets aggregate 0.31 · 2 independent evidence families

PoisoningModerately supported
0.51
agreement 0.390.63
Genetic100%

Open Targets aggregate 0.31 · 1 independent evidence family

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Nephrotic Syndrome0.46
Renal Insufficiency0.37
Smoking initiation0.34
Genetic Diseases, Inborn0.34
Immune System Diseases0.31
Poisoning0.31
Placental abruption0.29

Tractability

Small moleculesEmerging

Feasibility evidence (structure with ligand and high-quality ligand) — no clinical-stage drug of this modality recorded.

AntibodiesEmerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (half-life data and small molecule binder) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (8)
SM · Structure with LigandSM · High-Quality LigandSM · Druggable FamilyAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Research activity

2 papers · to 2024

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Europe PMC papers linked directly to this protein.